Acurx Pharmaceuticals (ACXP) Change in Receivables (2024 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Change in Receivables for 3 consecutive years, with $38994.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables fell 3.02% year-over-year to $38994.0; the trailing twelve-month figure through Jun 2026 stood at $55099.0 (up 604.62% YoY), and the FY2025 full-year result was -$2710.0, up 96.53% from the prior year.
• Change in Receivables grew to $38994.0 in Q2 2026 per ACXP's latest filing, from $7896.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $51127.0 in Q2 2024 and bottomed at -$129159.0 in Q1 2024.
• Historically, Change in Receivables has averaged -$3761.3 across 3 years, with a median of $8209.0 in 2025.
• The widest YoY moves for Change in Receivables: up 117.75% in 2025, down 21.36% in 2025.
• Over 3 years, Change in Receivables stood at -$46246.0 in 2024, then soared by 117.75% to $8209.0 in 2025, then surged by 375.02% to $38994.0 in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $38994.0, $7896.0, and $8209.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.